slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 21,961-21,990
Pages 1,349
Rows per page 30
Beat
21,961-21,990 of 40,452
19
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a list of three key regulatory takeaways followed by a forward-looking implication for the pipeline.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide introduces the drug candidate VLS-01, providing its chemical identity and current clinical trial status.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
26
The slide uses a process flow diagram to represent clinical trial cohorts and SMG (Safety Monitoring Group) review gates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
27
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
31
The slide uses topographical brain maps to visualize EEG data changes. Significant channels are marked with black circles.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
32
Slide 32 of a presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
33
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
34
The slide uses a vertical process flow to show the progression from pre-clinical to clinical phases, mapped against key de-risking milestones.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
35
The slide uses a grouped bar chart to show T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage groups.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
37
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
38
The slide uses a chemical structure diagram to establish the scientific basis for the product.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
39
The slide outlines two distinct clinical study parts: a Single Ascending Dose (SAD) study and a crossover comparator study.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
40
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
Uses a Venn-like containment diagram to show sub-segments of a larger market.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
14
The slide uses a hexagonal layout to present five key product attributes.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
15
The slide notes that BAER-101 was previously known as AZD7325.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Product1 hit
16
The slide highlights the therapeutic window of BAER-101 by showing efficacy in the punished model without significant impairment in the un-punished model.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Product1 hit
28
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Team1 hit
29
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Team1 hit
04
The slide combines corporate facts with team and board composition.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · Team1 hit
17
The table presents financial data in thousands of pounds (£'000) for the six months ended June 30th.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · Financials1 hit